Raymond James Financial’s 4D Molecular Therapeutics FDMT Stock Holding History

Raymond James Financial’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.22M	Sell	242,349 -23,798	-9%	-$232K	﹤0.01%	3108
2026 Q1	$2.48M	Sell	266,147 -211,358	-44%	-$1.84M	﹤0.01%	3182
2025 Q4	$3.58M	Buy	477,505 +6,235	+1%	+$63.2K	﹤0.01%	2786
2025 Q3	$4.1M	Buy	471,270 +15,800	+3%	+$94.4K	﹤0.01%	2609
2025 Q2	$1.69M	Buy	455,470 +161,091	+55%	+$566K	﹤0.01%	3217
2025 Q1	$951K	Buy	294,379 +181,475	+161%	+$855K	﹤0.01%	3530
2024 Q4	$629K	Buy	+112,904	New	+$886K	﹤0.01%	3763

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Raymond James Financial's FDMT Position: Q2 2026 in Review

Raymond James Financial reduced its 4D Molecular Therapeutics (FDMT) stake by 8.9% in Q2 2026, selling an estimated $232K and leaving 242,349 shares worth $3.22M. The position accounts for ﹤0.01% of the portfolio, ranked #3108.

Raymond James Financial first reported a position in FDMT in Q4 2024 and has held it in 7 quarters since. The position peaked at $4.1M in Q3 2025. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Raymond James Financial held 242,349 shares of 4D Molecular Therapeutics worth $3.22M as of Q2 2026.
Raymond James Financial sold 23,798 4D Molecular Therapeutics shares in Q2 2026, an estimated $232K.
4D Molecular Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3108 holding.
Raymond James Financial first reported a position in 4D Molecular Therapeutics in Q4 2024 and has held it in 7 quarters since.
Raymond James Financial's 4D Molecular Therapeutics position peaked at $4.1M in Q3 2025.
158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.